Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23449295 | 0.84 | DRD2 (0.44) | CHRNA7 | |
| SCHEMBL24493509 | 0.84 | HRH3 (0.45) | MAPK1 | |
| SCHEMBL27111350 | 0.83 | DRD2 (0.46) | ALDH1A1MAOAMAOBCHRNA7 | |
| SCHEMBL24775490 | 0.83 | DRD2 (0.46) | ALDH1A1MAOAMAOBCHRNA7 | |
| SCHEMBL21725645 | 0.82 | RIPK1 (0.54) | MAOAMAOBTSHR | |
| SCHEMBL4100913 | 0.82 | RIPK1 (0.54) | MAOAMAOBTSHR | |
| SCHEMBL19862551 | 0.81 | PARP1 (0.42) | CHRNA7MDM2 | |
| SCHEMBL19862566 | 0.81 | PARP1 (0.42) | CHRNA7MDM2 | |
| SCHEMBL24775502 | 0.81 | DRD2 (0.50) | ALDH1A1CHRNA7 | |
| SCHEMBL14213446 | 0.80 | CHRNB2 (0.59) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2021-06-03 | — | — | US | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | CDK6, IL6, CDK4 | MAPK1 432/4885ALDH1A1 1187/4885MAOA 2706/4885 |
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | MAPK1 1503/4885ALDH1A1 436/4885MAOA 132/4885 |
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | MAPK1 846/4885ALDH1A1 2019/4885MAOA 1897/4885 |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | MAPK1 432/4885ALDH1A1 1187/4885MAOA 2706/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | MAPK1 105/4885ALDH1A1 4302/4885MAOA 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.